Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Terconazole

Terconazole

pharmaceutical raw materials
Terconazole structure

Terconazole 

structure
  • CAS No:

    67915-31-5

  • Formula:

    C26H31Cl2N5O3

  • Chemical Name:

    Terconazole

  • Synonyms:

    Piperazine,1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-,rel-;Piperazine,1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-,cis-;rel-1-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)piperazine;Triaconazole;Terconazole;Gyno-Terazol;Terazol;Terazol Cream & Suppositories;R 42470;Fungistat;Tercospor;NSC 331942;(±)-Terconazole;Termayazole;85058-79-3

  • Categories:

    Analytical Chemistry  >  Standard

Description

Terconazole is a broad-spectrum antifungal medication for the treatment of vaginal yeast infection.


Solid


(2R,4S)-terconazole is a 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively. It is an enantiomer of a (2S,4R)-terconazole.|Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a triazole ketal derivative. Terconazole was initially approved by the FDA in 1987. This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials.

Terconazole Basic Attributes

532.46

532.46

267-751-6

760361

DTXSID2045498

G - Genito urinary system and sex hormones

2934990002

Characteristics

64.9

4.8

white

1.35g/cm3

126.3 °C

681.8°C at 760 mmHg

366.2ºC

1.64

DMSO: soluble 1mg/mL

2-8°C

Safety Information

NONH for all modes of transport

3

36/37/38-53

26

TL3564600

Xi

P305 + P351 + P338

H315-H319-H335-H413

|Warning|H302 (59.57%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P273, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 94 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

The oral LD50 values were found to be 1741 and 849 mg/kg for the male and female in rat.

94.9%

Drug Information

For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.|FDA Label

Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth.

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)

Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations|Following oral (30 mg) administration of 14C-labelled terconazole, excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes.

Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation.

6.9 hours (range 4.0-11.3)

Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.

1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine

Terconazole Use and Manufacturing

Uses

Terazol (Ortho-McNeil).

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:532.5
XLogP3:4.8
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:8
Exact Mass:531.1803953
Monoisotopic Mass:531.1803953
Topological Polar Surface Area:64.9
Heavy Atom Count:36
Complexity:693
Defined Atom Stereocenter Count:2
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Extract from the above information

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • W R GRACE AND CO -CONN

    United States United States
    Active
  • QUIMICA SINTETICA SA

    Spain Spain
    Active
  • Shanghai Shyndec Pharmaceutical Co., Ltd.

    China China
    Active

Recommended Suppliers of Terconazole

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.